Literature DB >> 29770011

Interim Recommendations for the Reporting of Extensively Drug Resistant and Pan Drug Resistant Isolates of Enterobacteriaceae, Pseudomonas aeruginosa, Acinetobacter spp. and Stenotrophomonas maltophilia.

G J German1, F B Jamieson2, M Gilmour3, H Almohri4, J Bullard5, M C Domingo6, J Fuller7, G Girouard8, D Haldane9, L Hoang10, P N Levett11, J Longtin6, R Melano2, R Needle12, S N Patel2, A Rebbapragada13, R C Reyes14, M R Mulvey3.   

Abstract

Entities:  

Year:  2016        PMID： 29770011      PMCID： PMC5864267          DOI： 10.14745/ccdr.v42i04a04

Source DB:  PubMed          Journal:  Can Commun Dis Rep        ISSN： 1188-4169


× No keyword cloud information.
  5 in total

Review 1.  EUCAST expert rules in antimicrobial susceptibility testing.

Authors:  R Leclercq; R Cantón; D F J Brown; C G Giske; P Heisig; A P MacGowan; J W Mouton; P Nordmann; A C Rodloff; G M Rossolini; C-J Soussy; M Steinbakk; T G Winstanley; G Kahlmeter
Journal:  Clin Microbiol Infect       Date:  2011-11-25       Impact factor: 8.067

2.  Population-based epidemiological study of infections caused by carbapenem-resistant Pseudomonas aeruginosa in the Calgary Health Region: importance of metallo-beta-lactamase (MBL)-producing strains.

Authors:  Kevin B Laupland; Michael D Parkins; Deirdre L Church; Daniel B Gregson; Thomas J Louie; John M Conly; Sameer Elsayed; Johann D D Pitout
Journal:  J Infect Dis       Date:  2005-09-26       Impact factor: 5.226

3.  Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance.

Authors:  A-P Magiorakos; A Srinivasan; R B Carey; Y Carmeli; M E Falagas; C G Giske; S Harbarth; J F Hindler; G Kahlmeter; B Olsson-Liljequist; D L Paterson; L B Rice; J Stelling; M J Struelens; A Vatopoulos; J T Weber; D L Monnet
Journal:  Clin Microbiol Infect       Date:  2011-07-27       Impact factor: 8.067

4.  Carbapenem-resistant Gram-negative bacilli in Canada 2009-10: results from the Canadian Nosocomial Infection Surveillance Program (CNISP).

Authors:  L F Mataseje; E Bryce; D Roscoe; D A Boyd; J Embree; D Gravel; K Katz; P Kibsey; M Kuhn; A Mounchili; A Simor; G Taylor; E Thomas; N Turgeon; M R Mulvey
Journal:  J Antimicrob Chemother       Date:  2012-03-07       Impact factor: 5.790

5.  Multi-drug resistant Acinetobacter infections in critically injured Canadian forces soldiers.

Authors:  Homer C Tien; Anthony Battad; Elizabeth A Bryce; Jeffrey Fuller; Michael Mulvey; Kathy Bernard; Ronald Brisebois; Jay J Doucet; Sandro B Rizoli; Robert Fowler; Andrew Simor
Journal:  BMC Infect Dis       Date:  2007-08-14       Impact factor: 3.090
  5 in total
  2 in total

1.  Canadian recommendations for laboratory interpretation of multiple or extensive drug resistance in clinical isolates of Enterobacteriaceae, Acinetobacter species and Pseudomonas aeruginosa.

Authors:  G J German; M Gilmour; G Tipples; H J Adam; H Almohri; J Bullard; T Dingle; D Farrell; G Girouard; D Haldane; L Hoang; P N Levett; R Melano; J Minion; R Needle; S N Patel; R Rennie; R C Reyes; J Longtin; M R Mulvey
Journal:  Can Commun Dis Rep       Date:  2018-01-04

2.  In Vitro Activity of Imipenem-Relebactam against Clinical Isolates of Gram-Negative Bacilli Isolated in Hospital Laboratories in the United States as Part of the SMART 2016 Program.

Authors:  James A Karlowsky; Sibylle H Lob; Krystyna M Kazmierczak; Katherine Young; Mary R Motyl; Daniel F Sahm
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.